EXOZ (eXoZymes Inc. Common Stock) Stock Analysis - News
eXoZymes Inc. Common Stock (EXOZ) is a publicly traded Healthcare sector company. As of May 21, 2026, EXOZ trades at $9.40 with a market cap of $80.97M and a P/E ratio of -8.83. EXOZ moved -2.11% today. Year to date, EXOZ is -15.50%; over the trailing twelve months it is -10.22%. Its 52-week range spans $7.08 to $23.99. Rallies surfaces EXOZ's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in EXOZ news today?
eXoZymes Graduates Shell GameChanger Program, Gains Multimillion-Dollar Support to Scale Platform: eXoZymes has graduated from Shell’s GameChanger Accelerator after three years of collaboration with the U.S. Department of Energy’s National Laboratory of the Rockies, gaining multimillion-dollar support and technical guidance to scale its cell-free biomanufacturing platform. The program funded technoeconomic analyses and optimized separations to de-risk AI-enhanced enzyme production.
Korman Tyler Paz sold 750 (~$7.89K) on Apr 9, 2026.
Korman Tyler Paz sold 750 (~$7.53K) on Apr 8, 2026.
Heltzen Michael bought 1.04K (~$10.63K) on Jul 2, 2025.
EXOZ Analyst Consensus
EXOZ analyst coverage data. Average price target: $0.00.
Common questions about EXOZ
What changed in EXOZ news today?
eXoZymes Graduates Shell GameChanger Program, Gains Multimillion-Dollar Support to Scale Platform: eXoZymes has graduated from Shell’s GameChanger Accelerator after three years of collaboration with the U.S. Department of Energy’s National Laboratory of the Rockies, gaining multimillion-dollar support and technical guidance to scale its cell-free biomanufacturing platform. The program funded technoeconomic analyses and optimized separations to de-risk AI-enhanced enzyme production.
Does Rallies summarize EXOZ news?
Yes. Rallies summarizes EXOZ news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is EXOZ research on Rallies investment advice?
No. Rallies provides research, data, and educational context for EXOZ. It does not provide personalized investment advice.
